PPD Expands GMP Lab Testing Capabilities for Biologics

Enhances gene and cell therapy lab services across Europe and North
America

WILMINGTON, N.C.–(BUSINESS WIRE)–Pharmaceutical Product Development, LLC (PPD)
is adding gene and cell therapy analytical testing to its GMP (good
manufacturing practices) laboratory in Athlone, Ireland, to support the
pharmaceutical industry’s growing need for biologics testing. The
enhancements in PPD®
Laboratories’
Athlone location complement the ongoing capacity and
capability expansions at its flagship GMP lab in Middleton, Wisconsin,
enabling the company to expand the global reach of its industry-leading
biologics testing services.


“PPD Laboratories has been focused on providing cutting-edge gene and
cell therapy analytical testing services and capabilities around the
world,” said Jon Denissen, Ph.D., senior vice president of the company’s
bioanalytical and GMP labs. “These changes in Athlone are part of our
ongoing plan to ultimately mirror there the upgrades we’ve been
incorporating in Middleton. Our goal is to offer the same extensive
biologic, gene and cell therapy portfolio to clients in both Europe and
North America, giving them additional opportunity to bring their valued
assets to our scientific professionals at either GMP location.”

The GMP lab expansion will add nearly 6,000 square feet (540 square
meters) of new lab space to the existing 41,000 square feet (3,850
square meters) at the Athlone facility. The new space will be primarily
devoted to biologics testing and will enable the company to add
quantitative polymerase chain reaction (qPCR) platforms for contaminant
testing for biologics, which is a new capability for the Athlone
location. The company anticipates adding about 20 positions as a result
of the expansion.

PPD
Laboratories’ GMP lab
is a leading provider of chemistry,
manufacturing and controls (CMC) laboratory services for all phases of
drug development.

The Athlone GMP lab offers fully integrated solutions for pharmaceutical
product development, including analytical testing services, stability
testing, quality control and release testing. In addition to biologic
testing, the laboratory is a market leader in the analysis of small
molecule and inhalation products, as well as extractables and leachables
testing.

In addition to the GMP labs in Athlone and Middleton, PPD Laboratories’
operations also include a bioanalytical lab in Middleton; vaccine
sciences, bioanalytical and biomarker labs in Richmond, Virginia;
central labs in Shanghai, China; Brussels, Belgium; Highland Heights,
Kentucky; and Singapore; and a biomarker lab in Highland Heights.

About PPD
PPD is a leading global contract research
organization providing comprehensive, integrated drug development,
laboratory and lifecycle management services. Our clients and partners
include pharmaceutical, biotechnology, medical device, academic and
government organizations. With offices in 47 countries and approximately
20,000 professionals worldwide, PPD applies innovative technologies,
therapeutic expertise and a firm commitment to quality to help clients
and partners bend the cost and time curve of drug development and
optimize value in delivering life-changing therapies to improve health.
For more information, visit www.ppdi.com.

Contacts

Media:
Randy Buckwalter
+1 919 456 4425
randy.buckwalter@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com